Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 120Carcinoma, Hepatocellular 69Ovarian Neoplasms 64Neoplasms 36Carcinoma, Non-Small-Cell Lung 35Fallopian Tube Neoplasms 29Brain Neoplasms 24Glioblastoma 23Colonic Neoplasms 21Breast Neoplasms 19Endometrial Neoplasms 18Neoplasm Metastasis 17Uterine Cervical Neoplasms 15Stomach Neoplasms 15Rectal Neoplasms 15Lung Neoplasms 14Liver Neoplasms 11Triple Negative Breast Neoplasms 10Melanoma 8Glioma 8Carcinoma, Renal Cell 8Carcinoma, Ovarian Epithelial 8Biliary Tract Neoplasms 8Recurrence 7Colorectal Cancer Metastatic 7Squamous Cell Carcinoma of Head and Neck 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Advanced Solid Tumors 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5

Interventions

Cisplatin 7Gemcitabine 6pembrolizumab 4Radiotherapy, Intensity-Modulated 4toripalimab 2Bevacizumab 2tocilizumab 1tislelizumab 1spartalizumab 1penpulimab 1atezolizumab 1Vitamin D 1Tablets 1Surveys and Questionnaires 1Phantoms, Imaging 1Oral Hygiene 1Observation 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Immunohistochemistry 1Immunoglobulin G 1Fluorouracil 1Disulfides 1Dexamethasone 1Chemoradiotherapy 1Cetuximab 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × Bevacizumab × 1 year × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT05305131 2025-09-23

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

National University Hospital, Singapore

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡